Acne Vulgaris
📧 Sign up to get email alerts when something new happens for Acne Vulgaris.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-09-13FDA Approved: TAZAROTENE — Original Application (Cosette Pharmaceuticals, Inc.)
FDA approved Cosette Pharmaceuticals' generic tazarotene through an Original Application (ANDA 215433). The product is intended for the trea…
-
FDA approval · 2022-08-25FDA Approved: ADAPALENE — Supplemental Application (Mayne Pharma Commercial LLC.)
FDA approves a supplemental application for adapalene from Mayne Pharma Commercial LLC., likely related to labeling updates for acne treatme…
-
FDA approval · 2022-08-24FDA Approved: ISOTRETINOIN — Supplemental Application (Mayne Pharma)
FDA approved a supplemental application for isotretinoin submitted by Mayne Pharma.
-
FDA approval · 2022-08-24FDA Approved: ISOTRETINOIN — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for isotretinoin from Upsher-Smith Laboratories, LLC.
-
FDA approval · 2022-08-24FDA Approved: ISOTRETINOIN — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for isotretinoin submitted by Upsher-Smith Laboratories, LLC. This document indicates a suppleme…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-08-23FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for CLARAVIS (isotretinoin) from Teva Pharmaceuticals USA, Inc., authorizing changes to the prod…
-
FDA approval · 2022-08-23FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for CLARAVIS (isotretinoin) from Teva Pharmaceuticals USA, Inc., indicating regulatory clearance…
-
FDA approval · 2022-08-23FDA Approved: AMNESTEEM — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for AMNESTEEM (isotretinoin) filed by Mylan Pharmaceuticals Inc. The document indicates an appro…
-
FDA approval · 2022-08-23FDA Approved: ZENATANE — Supplemental Application (BluePoint Laboratories)
FDA approves a supplemental application for ZENATANE (isotretinoin) filed by BluePoint Laboratories.
-
FDA approval · 2022-08-04FDA Approved: ZENATANE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for Zenatane (isotretinoin) by BluePoint Laboratories.
-
FDA approval · 2022-08-04FDA Approved: ADAPALENE AND BENZOYL PEROXIDE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' original application for Adapalene and benzoyl peroxide topical for acne vulgaris.
-
FDA approval · 2022-07-19FDA Approved: AKLIEF — Supplemental Application (Galderma Laboratories, L.P.)
This FDA document concerns a supplemental application for AKLIEF (trifarotene) submitted by Galderma Laboratories, L.P.
-
FDA approval · 2022-07-01FDA Approved: AZELAIC ACID GEL — Supplemental Application (Encube Ethicals, Inc.)
FDA approved a supplemental application for AZELAIC ACID GEL from Encube Ethicals, Inc. under ANDA208724.
-
FDA approval · 2022-06-22FDA Approved: ADAPALENE AND BENZOYL PEROXIDE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved Teva's Original Application for a generic adapalene with benzoyl peroxide topical acne treatment. It provides a generic option …
-
FDA approval · 2022-06-14FDA Approved: DIFFERIN — Supplemental Application (Galderma Laboratories, L.P.)
FDA approved a supplemental application for Differin (adapalene) filed by Galderma Laboratories, L.P.
-
FDA approval · 2022-06-03FDA Approved: ADAPALENE AND BENZOYL PEROXIDE — Original Application (Zydus Lifesciences Limited)
FDA approved the original ANDA for a generic combination of adapalene and benzoyl peroxide from Zydus Lifesciences Limited for acne vulgaris…
-
FDA approval · 2022-05-31FDA Approved: ADAPALENE AND BENZOYL PEROXIDE — Original Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a new original application for a topical combination of adapalene and benzoyl peroxide for acne vulgaris, developed by Padagis …
-
FDA approval · 2022-04-27FDA Approved: EPIDUO FORTE — Supplemental Application (Galderma Laboratories, L.P.)
FDA approved a supplemental application for Epiduo Forte (adapalene and benzoyl peroxide) by Galderma Laboratories, L.P.
-
FDA approval · 2022-04-07FDA Approved: ABSORICA LD — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for ABSORICA LD (isotretinoin) from Sun Pharmaceutical Industries, Inc. This action approves a suppl…
-
FDA approval · 2022-02-10FDA Approved: CLINDAMYCIN PHOSPHATE AND TRETINOIN — Original Application (Solaris Pharma Corporation)
The FDA approved Solaris Pharma Corporation's clindamycin phosphate and tretinoin as an original application, a topical combination product …
-
FDA approval · 2022-01-14FDA Approved: ADAPALENE — Original Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical's generic adapalene in an original [ANDA] application for topical use to treat acne vulgaris. This marks…
-
FDA approval · 2022-01-13FDA Approved: AMZEEQ — Supplemental Application (Journey Medical Corporation)
FDA approved a supplemental application for AMZEEQ (minocycline) by Journey Medical Corporation. The action relates to the approval of a sup…
-
FDA approval · 2021-11-09FDA Approved: ZENATANE — Supplemental Application (BluePoint Laboratories)
FDA approves a supplemental application for ZENATANE (isotretinoin) submitted by BluePoint Laboratories.
-
FDA approval · 2021-11-08FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for CLARAVIS (isotretinoin) from Teva Pharmaceuticals USA, Inc. This action updates the approval sta…
-
FDA approval · 2021-11-08FDA Approved: AMNESTEEM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for AMNESTEEM (isotretinoin) by Mylan Pharmaceuticals Inc.